|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-16.80/1.77
|
企业价值
1.24B
|
资产负债 |
每股账面净值
1.14
|
现金流量 |
现金流量率
--
|
损益表 |
收益
1.21B
|
每股收益
4.04
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/04 23:52 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy. |